Background
==========

Intentional ingestion of organophosphate insecticide causes many deaths each year in Taiwan \[[@B1]\]. Chronologically, the 3 different clinical syndromes after acute organophosphate intoxication include (1) early acute cholinergic crisis due to acetylcholinesterase suppression, (2) intermediate syndrome (0.5--7 days) that has an unclear underlying mechanism, and (3) delayed polyneuropathy (6--21 days) explained by the inhibition of neuropathy target esterase. Acute cholinergic crisis \[[@B2]\] includes signs and symptoms resulting from hyperstimulation of muscarinic receptors in the parasympathetic system (e.g., bradycardia, bronchospasm, bronchorrhea, hypotension, diarrhea, vomiting, miosis, lachrymation, salivation, and urination), nicotinic receptors in the sympathetic system (e.g., hypertension, tachycardia, mydriasis, and sweating), nicotinic receptors at the neuromuscular junction (e.g., muscle weakness, paralysis, and fasciculations), and both central muscarinic and nicotinic receptors in the central nervous system (e.g., confusion, agitation, coma, and respiratory failure).

We performed this study because, as demonstrated previously, diabetes mellitus could modify drug pharmacokinetics by altering hepatic drug-metabolizing enzyme activity \[[@B3],[@B4]\]. In addition, Starr et al \[[@B5]\] found that increased blood-brain barrier permeability with magnetic resonance imaging was detected in patients with type II diabetes or white matter hyperintensities. Increased permeability of the blood-brain barrier might account for some of the cerebral effects of type II diabetes, and so possibly also for the effect of other conditions that affect the microvasculature (like hypertension), on the brain. Therefore, we hypothesized that diabetic patient with organophosphates poisoning might suffer from a higher mortality rate than patients without diabetes.

We also performed this study because several reports have shown that organophosphates might have a special effect on the mammalian pancreas \[[@B6]\], especially on glucose homeostasis and the possibility of new-onset diabetes mellitus \[[@B7],[@B8]\]. Therefore, we investigated the mortality rates of patients with and without diabetes mellitus after acute large-dose exposure to organophosphate insecticides. In addition, all patients without diabetes mellitus were traced to examine the short to medium term risk of new-onset diabetes mellitus.

Methods
=======

This retrospective observational study complied with the Declaration of Helsinki guidelines and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital, a tertiary referral center located in the northern part of Taiwan. Because this study was a retrospective review of existing data, Institutional Review Board approval was obtained, but without specific informed consent from the patients. However, informed consent of acute organophosphate poisoning risk and all treatment modalities (including cardiopulmonary cerebral resuscitation, etc.) was obtained from all patients at their initial admission. In addition, all individual information was securely protected (by delinking identifying information from the main data set) and was available to investigators only. Furthermore, all data were analyzed anonymously. The Institutional Review Board of Chang Gung Memorial Hospital specifically waived the need for consent. Finally, all primary data were collected according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. This policy was based on previous publications \[[@B9],[@B10]\].

Patients
--------

We analyzed the records of 118 patients with intentional organophosphate poisoning examined at Chang Gung Memorial Hospital between 2000 and 2011. The diagnosis of organophosphate poisoning was based on history of exposure, clinical effects, and serum cholinesterase activity. Serum cholinesterase activity was determined using an enzymatic method (normal values: 7--19 U/mL) immediately after the patient arrived at the hospital. The pesticide ingested was determined by history, container label, or product information provided by the patient. A complete clinical profile of each patient was recorded using a standardized form. We obtained the following data for each patient: age, sex, blood pressure, heart rate, type and toxicity classification of the organophosphate, underlying diseases, smoking habits, alcohol consumption, medications, time elapsed between poisoning and hospital arrival, duration of follow-up, clinical manifestations, electrocardiogram results, serum cholinesterase level, hemogram, biochemistry, the detoxification protocol used, and mortality.

Inclusion and exclusion criteria
--------------------------------

All patients aged \>18 years diagnosed with organophosphate poisoning at Chang Gung Memorial Hospital between 2000 and 2011 were eligible for inclusion in this study. Patients were excluded if they were aged \<18 years or did not have suppressed serum cholinesterase levels despite suspicions of exposure.

Detoxification protocols
------------------------

The protocols \[[@B10]\] used to treat patients included gastric lavage with large amounts of normal saline, followed by infusion of 1 g/kg activated charcoal and 250 mL of magnesium citrate administered via a nasogastric tube. Magnesium citrate was used to prevent constipation after charcoal administration. Patients were also treated with specific antidotes including atropine and oximes. Intravenous atropine was administered at a starting dose of 2 mg every 1--2 hours, and dosing was titrated to the clearing of respiratory secretions and cessation of bronchoconstriction. All patients with evidence of cholinergic toxicity were given pralidoxime therapy (1 g every 4 hours administered intravenously).

Definition of clinical events
-----------------------------

We classified organophosphate toxicity using the following formal World Health Organization recommendations: class Ia (extremely hazardous), class Ib (highly hazardous), class II (moderately hazardous), class III (slightly hazardous), and class U (unlikely to present acute hazard) \[[@B11]\]. Acute renal failure was diagnosed if the serum creatinine level increased to \>1.27 mg/dL in men or 1.03 mg/dL in women. Acute respiratory failure was defined as a condition of respiratory insufficiency requiring intubation and mechanical ventilation for more than 24 hours, regardless of the fraction of inspired oxygen \[[@B12]\]. Hypotension was defined as systolic blood pressure \<90 mm Hg. Structural heart disease was defined as noncoronary cardiovascular disease processes and related interventions \[[@B13]\]. Use of medications that might be associated with corrected QT interval (QTc) prolongation was recorded. In this regard, the antiarrhythmic agents included class Ia, class Ic, and class III agents \[[@B14]\]. Antimicrobials included macrolides/ketolides, certain fluoroquinolones, certain antimalarials, pentamidine, and azole antifungals \[[@B15]\]. Antipsychotics and antidepressants included (1) typical antipsychotics such as chlorpromazine, pimozide, thioridazine, perphenazine, trifluoperazine, haloperidol, and droperidol; (2) atypical antipsychotics such as clozapine, quetiapine, risperidone, sultopride, ziprasidone, and loxapine; (3) tricyclic antidepressants such as amitriptyline, amoxapine, clomipramine, desipramine, citalopram, doxepin, imipramine, nortriptyline, and trimipramine; and (4) other antidepressants such as fluoxetine, sertraline, and venlafaxine \[[@B16]\]. New-onset diabetes mellitus was defined as casual plasma glucose ≥200 mg/dL \[[@B17],[@B18]\] that occurred in patients without pre-existing diabetes mellitus.

Statistical analysis
--------------------

Continuous variables are expressed as the mean and standard deviation and categorical variables as the number with percentage in brackets. All data were tested for normality of distribution and equality of standard deviations before analysis. For comparisons between patient groups, we used Student\'s *t*-test for quantitative variables and chi-square or Fisher\'s exact test for categorical variables. Mortality data were compared using the Kaplan-Meier method and significance was tested using a log rank test. An initial univariate Cox regression analysis was performed to compare the frequency of possible risk factors associated with mortality. To control for possible confounding factors, a multivariate Cox regression analysis (backward stepwise approach) was performed to analyze factors that were significant in univariate models (P \< 0.05) and met the assumptions of a proportional hazards model. Results that rejected the null hypothesis with 95% confidence were considered significant. All analyses were performed using SPSS, version 12.0 for Windows (SPSS Inc., Chicago, Illinois, USA).

Results
=======

Table  [1](#T1){ref-type="table"} shows the baseline characteristics of the 118 patients with organophosphate poisoning overall and by diabetes mellitus status. Of the 118 patients, 109 were in the non--diabetes mellitus group and 9 were in the diabetes mellitus group. Most of the patients were middle aged (53.45 ± 16.20 years) and men (65.3%) and were referred to our hospital after a relatively short amount of time had elapsed since poisoning (median 3.0 hours). Notably, nearly half of the patients had a history of a mental disorder (43.2%) and were undergoing long-term treatment with antipsychotic and antidepressant medications (25.4%). After analysis, we found that patients with diabetes mellitus were older than patients without diabetes mellitus (52.32 ± 16.04 versus 67.11 ± 11.84 years; P = 0.008). Otherwise, there were no significant differences in baseline variables between the groups (P \> 0.05).

###### 

Baseline characteristics of patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)

  **Variable**                                                                 **Total (N = 118)**   **Non-diabetes mellitus (N = 109)**   **Diabetes mellitus (N = 9)**   **P**
  ---------------------------------------------------------------------------- --------------------- ------------------------------------- ------------------------------- -----------
  Age, years (mean ± SD)                                                       53.45 ± 16.20         52.32 ± 16.04                         67.11 ± 11.84                   0.008\*\*
  Male, n (%)                                                                  77 (65.3)             73 (67.0)                             4 (44.4)                        0.173
  Organophosphate type, n (%):                                                                                                                                             0.082
  Chlorpyrifos                                                                 48 (40.7)             44 (40.4)                             4 (44.4)                         
  Profenofos                                                                   16 (13.6)             16 (14.7)                             0 (0.0)                          
  Methamidophos                                                                14 (11.9)             14 (12.8)                             0 (0.0)                          
  Mevinphos                                                                    10 (8.5)              9 (8.3)                               1 (11.1)                         
  Dimethoate                                                                   9 (7.6)               8 (7.3)                               1 (11.1)                         
  Malathion                                                                    6 (5.1)               5 (4.6)                               1 (11.1)                         
  Parathion                                                                    4 (3.4)               4 (3.7)                               0 (0.0)                          
  Acephate                                                                     3 (2.5)               2 (1.8)                               1 (11.1)                         
  Trichlorfon                                                                  3 (2.5)               3 (2.8)                               0 (0.0)                          
  Terbufos                                                                     2 (1.7)               2 (1.8)                               0 (0.0)                          
  Dichlorvos                                                                   1 (0.8)               1 (0.9)                               0 (0.0)                          
  Fenamiphos                                                                   1 (0.8)               1 (0.9)                               0 (0.0)                          
  Phorate                                                                      1 (0.8)               0 (0.0)                               1 (11.1)                         
  Organophosphate toxicity, n (%):                                                                                                                                         0.206
  Ia, extremely hazardous                                                      17 (14.4)             15 (13.8)                             2 (22.2)                         
  Ib, highly hazardous                                                         16 (13.6)             16 (14.7)                             0 (0.0)                          
  II, moderately hazardous                                                     76 (64.4)             71 (65.1)                             5 (55.6)                         
  III, slightly hazardous                                                      9 (7.6)               7 (6.4)                               2 (22.2)                         
  U, unlikely to present acute hazard                                          0 (0)                 0 (0)                                 0 (0)                            
  Hypertension, n (%)                                                          21 (17.8)             18 (16.5)                             3 (33.3)                        0.199
  Old stroke, n (%)                                                            10 (8.5)              8 (7.3)                               2 (22.2)                        0.123
  Coronary artery disease, n (%)                                               3 (2.5)               3 (2.8)                               0 (0.0)                         0.614
  Structural heart disease, n (%)                                              11 (9.3)              10 (9.2)                              1 (11.1)                        0.848
  Chronic obstructive pulmonary disease, n (%)                                 9 (7.6)               8 (7.3)                               1 (11.1)                        0.682
  Malignancy, n (%)                                                            3 (2.5)               3 (2.8)                               0 (0.0)                         0.614
  Mental disorder, n (%)                                                       51 (43.2)             46 (42.2)                             5 (55.6)                        0.437
  Smoking habit, n (%)                                                         52 (44.1)             50 (45.9)                             2 (22.2)                        0.170
  Alcohol consumption, n (%)                                                   49 (41.5)             47 (43.1)                             2 (22.2)                        0.221
  Use of medications that might be associated with QTc 7prolongation, n (%):                                                                                                
  Antiarrhythmic agents                                                        20 (16.9)             17 (15.6)                             3 (33.3)                        0.173
  Antipsychotics and antidepressants                                           30 (25.4)             27 (24.8)                             3 (33.3)                        0.571
  Antimicrobials                                                               10 (8.5)              9 (8.3)                               1 (11.1)                        0.768

QTc, corrected QT interval.

Note: \*\*P \< 0.01.

After ingestion, the patients developed acute cholinergic crisis (Table  [2](#T2){ref-type="table"}) that included respiratory failure (51.7%), emesis (35.6%), diarrhea (29.7%), hypotension (22.9%), coma (19.5%), acute renal failure (9.3%), and seizure (8.5%), among other conditions. Intermediate syndrome and delayed polyneuropathy were also present in 8.5% and 2.5% of patients, respectively. Nevertheless, there were no significant differences in clinical variables between the groups (P \> 0.05). Laboratory analysis revealed suppressed initial and nadir serum cholinesterase levels (3.29 ± 3.53 U/mL and 2.79 ± 3.06 U/mL, respectively) (Table  [3](#T3){ref-type="table"}). There were no significant differences in laboratory variables between the groups (P \> 0.05).

###### 

Clinical manifestations of patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)

  **Variable**                           **Total (N = 118)**   **Non--diabetes mellitus (N = 109)**   **Diabetes mellitus (N = 9)**   **P**
  -------------------------------------- --------------------- -------------------------------------- ------------------------------- -------
  1\. Cholinergic crisis                                                                                                               
  Cardiovascular system:                                                                                                               
  Systolic BP, mm Hg (mean ± SD)         116.81 ± 23.21        117.46 ± 22.98                         108.89 ± 26.00                  0.289
  Diastolic BP, mm Hg (mean ± SD)        79.68 ± 18.24         80.30 ± 17.88                          72.11 ± 21.92                   0.197
  Heart rate, beats/minute (mean ± SD)   102.04 ± 26.72        103.26 ± 27.75                         91.43 ± 11.10                   0.270
  Hypotension, n (%)                     27 (22.9)             24 (22.0)                              3 (33.3)                        0.437
  Gastrointestinal system, n (%):                                                                                                      
  Diarrhea                               35 (29.7)             35 (32.1)                              0 (0.0)                         0.053
  Emesis                                 42 (35.6)             40 (36.7)                              2 (22.2)                        0.383
  Respiratory system, n (%):                                                                                                           
  Shortness of breath                    81 (68.6)             75 (68.8)                              6 (66.7)                        0.894
  Bronchorrhea                           72 (61.0)             66 (60.6)                              6 (66.7)                        0.718
  Bronchospasm                           67 (56.8)             61 (56.0)                              6 (66.7)                        0.533
  Respiratory failure                    61 (51.7)             55 (50.5)                              6 (66.7)                        0.350
  Genitourinary system n (%):                                                                                                          
  Acute renal failure                    11 (9.3)              10 (9.2)                               1 (11.1)                        0.848
  Central nervous system n (%):                                                                                                        
  Seizure                                10 (8.5)              8 (7.3)                                2 (22.2)                        0.123
  Coma                                   23 (19.5)             21 (19.3)                              2 (22.2)                        0.830
  2\. Intermediate syndrome, n (%)       10 (8.5)              10 (9.2)                               0 (0.0)                         0.342
  3\. Delayed polyneuropathy, n (%)      3 (2.5)               3 (2.8)                                0 (0.0)                         0.614

SD, standard deviation; BP, blood pressure.

###### 

Laboratory findings of patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)

  **Variable (mean ± SD)**         **Total (N = 118)**   **Non--diabetes mellitus (N = 109)**   **Diabetes mellitus (N = 9)**   **P**
  -------------------------------- --------------------- -------------------------------------- ------------------------------- -------
  Hemoglobin, g/dL                 14.33 ± 1.91          14.37 ± 1.95                           13.81 ± 1.30                    0.428
  Blood urea nitrogen, mg/dL       16.74 ± 16.45         16.34 ± 16.71                          25.20 ± 4.53                    0.463
  Creatinine, mg/dL                1.06 ± 0.72           1.05 ± 0.74                            1.14 ± 0.47                     0.741
  Sodium, mEq/L                    140.97 ± 3.68         141.04 ± 3.72                          140.13 ± 3.40                   0.502
  Potassium, mEq/L                 3.50 ± 0.54           3.48 ± 0.51                            3.75 ± 0.76                     0.167
  Cholinesterase (initial), U/mL   3.29 ± 3.53           3.18 ± 3.24                            4.67 ± 6.31                     0.254
  Cholinesterase (lowest), U/mL    2.79 ± 3.06           2.65 ± 2.65                            4.65 ± 6.28                     0.400
  C-reactive protein, mg/dL        8.18 ± 18.67          8.13 ± 19.31                           8.77 ± 15.65                    0.616
  Amylase, U/L                     195.98 ± 167.47       197.62 ± 162.72                        176.18 ± 187.21                 0.910
  Lipase, U/L                      113.50 ± 115.10       113.89 ± 117.96                        108.74 ± 84.24                  0.365
  CK-MB, ng/mL                     17.98 ± 61.03         17.56 ± 64.77                          23.07 ± 48.23                   0.691
  Troponin-I, ng/mL                0.07 ± 0.13           0.08 ± 0.14                            0.05 ± 0.12                     0.618
  QT interval, ms                  369.07 ± 57.59        366.61 ± 58.56                         390.57 ± 46.20                  0.301
  QTc interval, ms                 443.18 ± 52.71        440.21 ± 52.96                         479.29 ± 53.52                  0.236

SD, standard deviation; CK-MB, creatinine kinase MB; QTc, corrected QT interval.

As shown in Table  [4](#T4){ref-type="table"}, most patients were aggressively treated with gastric lavage with large amounts of normal saline, followed by an infusion of 1 g/kg activated charcoal and 250 mL of magnesium citrate. In addition, nearly all patients were administered systemic atropine and pralidoxime injections. There was no difference in treatment modality between the groups except a slightly lower use of atropine in the diabetes mellitus group compared with the non-diabetes mellitus group (88.9% versus 99.1%; P = 0.023).

###### 

Detoxification protocol and treatment outcome for patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)

  **Variable**                                           **Total (N = 118)**   **Non--diabetes mellitus (N = 109)**   **Diabetes mellitus (N = 9)**   **P**
  ------------------------------------------------------ --------------------- -------------------------------------- ------------------------------- ---------
  Gastric lavage, n (%)                                  95 (80.5)             89 (81.7)                              6 (66.7)                        0.275
  Active charcoal and magnesium citrate, n (%)           88 (74.6)             83 (76.1)                              5 (55.6)                        0.173
  Atropine, n (%)                                        116 (98.3)            108 (99.1)                             8 (88.9)                        0.023\*
  Pralidoxime, n (%)                                     115 (97.5)            107 (98.2)                             8 (88.9)                        0.089
  Time from poisoning to hospital, hours (median, IQR)   3.0 (2.0, 5.0)        3.0 (2.0, 5.0)                         3.5 (2.0, 9.0)                  0.893
  Duration of follow-up, months (median, IQR)            1.25 (0.40, 9.06)     1.23 (0.43, 8.63)                      2.27 (0.25, 15.67)              0.219
  Mortality, n (%)                                       18 (15.3)             15 (13.8)                              3 (33.3)                        0.117
  Cause of death, n (%)                                                                                                                               0.333
  Cardiogenic                                            10 (8.5)              8 (7.3)                                2 (22.2)                         
  Respiratory failure                                    6 (5.1)               5 (4.6)                                1 (11.1)                         
  Sepsis                                                 2 (1.7)               2 (1.8)                                0 (0.0)                          

IQR, interquartile range.

Note: \*P \< 0.05.

The median follow-up duration was 1.25 months. 18 (15.3) of 118 patients died, including 15 (13.8%) of 109 patients without diabetes mellitus and 3 (33.3%) of 9 patients with diabetes mellitus. There was no significant difference in mortality between the groups (P = 0.117) (Table  [4](#T4){ref-type="table"}). Similarly, there was no difference in the cause of mortality between patients with and without diabetes mellitus (P = 0.333).

A multivariate Cox regression model demonstrated that hypotension, respiratory failure, coma, and QTc prolongation were significant risk factors for mortality (Table  [5](#T5){ref-type="table"}). Notably, diabetes mellitus status was not a significant variable according to this model (P = 0.117).

###### 

Univariate and multivariate Cox regression analysis for mortality (N = 118)

  **Variable**          **Univariate analysis OR (95% CI)**   **P**         **Multivariate analysis OR (95% CI)**   **P**
  --------------------- ------------------------------------- ------------- --------------------------------------- -------------
  Hypotension           21.596 (6.237--74.780)                0.000\*\*\*   10.930 (2.961--40.345)                  0.000\*\*\*
  Respiratory failure   8.504 (1.955--36.997)                 0.004\*\*     4.867 (1.062--22.301)                   0.042\*
  Coma                  10.317 (3.857--27.595)                0.000\*\*\*   3.482 (1.184--10.238)                   0.023\*
  QTc prolongation      9.974 (2.885--34.478)                 0.000\*\*\*   7.459 (2.053--27.099)                   0.002\*\*
  Diabetes mellitus     2.634 (0.762--9.103)                  0.126                                                  

QTc, corrected QT interval.

Note: \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001.

Regarding the possibility of new-onset diabetes mellitus, all 94 of 109 non--diabetes mellitus patients were successfully traced at least 1 time between 2000 and 2012 except 15 patients died during admission. The random blood sugar level was checked during follow-up. At routine outpatient follow up a median of 1.25 months post exposure, random blood glucose measurements gave no evidence of new-onset diabetes in patients without pre-existing diabetes. The other 6 of 9 diabetes mellitus patients were successfully traced as well except 3 patients died during admission (Table  [6](#T6){ref-type="table"}).

###### 

Random blood glucose test after acute large-dose exposure to organophosphates in patients with and without diabetes mellitus (N = 118)

  **Variable (mean ± SD)**                **Total (N = 118)**   **Non--diabetes mellitus (N = 109)**   **Diabetes mellitus (N = 9)**   **P**
  --------------------------------------- --------------------- -------------------------------------- ------------------------------- -------------
  Sugar, mg/dL (during hospitalization)   164.3 ± 83.1          144.7 ± 43.6                           279.8 ± 10151.0                 0.000\*\*\*
  Sugar, mg/dL (after discharge)          142.2 ± 53.7          124.9 ± 22.5                           244.0 ± 71.0                    0.000\*\*\*

SD, standard deviation.

Note: \*\*\*P \< 0.001.

Discussion
==========

This study is of particular interest because it showed that diabetes mellitus status might not increase mortality risk following acute large-dose exposure to organophosphates (P = 0.117) (Table  [4](#T4){ref-type="table"}). Furthermore, the risk of new-onset diabetes mellitus after acute intoxication within the short term also might be minimal.

The relationship between organophosphate exposure and subsequent new-onset diabetes mellitus remains unclear. A previous animal study \[[@B19]\] found that dimethoate at subchronic oral doses had the propensity to impair glucose homeostasis and induce significant pancreatic damage, and also provide an account of the associated oxidative damage to pancreatic tissue in adult rats. Additionally \[[@B20]\], the toxicity of diazinon and its metabolites increases in diabetic rats. Slotkin \[[@B21]\] also reported that organophosphate exposure in neonatal rats during a critical developmental window altered the trajectory of hepatic adenylyl cyclase/cyclic AMP signaling, culminating in hyperresponsiveness to gluconeogenic stimuli. Consequently, the rats developed a metabolic dysfunction resembling prediabetes. Finally, it has been shown \[[@B22]\] that low-dose administration of chlorpyrifos in rats resulted in decreased activity of paraoxonase in serum, which was accompanied by an increased level of lipid peroxides. This oxidative stress might explain the further development of arteriosclerosis, hypercholesterolemia, and diabetes mellitus in people exposed to organophosphate compounds.

Shobha et al \[[@B23]\] reported transient glycosuria in 69% of patients after organophosphate poisoning. However, none of the patients had new-onset diabetes mellitus and the pre--hospital discharge blood sugars were in the normal range. Conversely \[[@B24]-[@B26]\], organophosphate intoxication presenting as diabetic ketoacidosis has been repeatedly reported in the pediatric population. Using data from the Agricultural Health Study, Saldana et al \[[@B7]\] found that activities involving exposure to agricultural pesticides during the first trimester of pregnancy might increase the risk of gestational diabetes mellitus. In another study using Agricultural Health Study data \[[@B8]\], it was proven that long-term exposure to dichlorvos and trichlorfon among licensed pesticide applicators could increase the risk of incident diabetes mellitus. Finally, a systematic review in 2010 \[[@B27]\] revealed that organophosphates impair the enzymatic pathways involved in the metabolism of carbohydrates within cytoplasm, mitochondria, and peroxisomes. Organophosphates exert this effect by inhibiting acetyl cholinesterase or affecting target organs (such as the pancreas, liver, muscles, and brain) directly. Furthermore, organophosphates also induce cellular oxidative stress by affecting mitochondrial function and therefore disrupt the neuronal and hormonal status of the body. Taken together, both central (pancreas) and peripheral glucose regulatory mechanisms could be impaired after organophosphate exposure \[[@B27]\].

In this study, it was found that the diabetic cohort had lesser load of poisoining as evidenced by the levels of initial cholinesterase (4.67 U/mL versus 3.18 U/mL; P = 0.254) and needed less atropine (99.1% versus 88.9%; P = 0.023). It is also possible that the mortality rates were affected by the less severe load in patient with diabetes mellitus. Nevertheless, the incidence of significant risk factors for mortality such as hypotension (22.0% versus 33.3%), respiratory failure (50.5% versus 66.7%), and coma (19.3% versus 22.2%) were higher in patient with diabetes mellitus. Small patient population may be the reason of non-significance in mortality rate between patient with and without diabetes mellitus.

A multivariate Cox regression analysis (Table  [5](#T5){ref-type="table"}) confirmed that hypotension, respiratory failure, coma, and QTc prolongation were significant risk factors for mortality after organophosphate poisoning. The associations between both hypotension \[[@B28]\] and coma with mortality were not surprising because both are important vital signs, irrespective of the cause of disease. Similarly, it was not surprising to find an association between respiratory failure and mortality because respiratory failure is a prominent feature of acute organophosphate poisoning with an early central apnea followed by later pulmonary effects \[[@B29]\]. Animal studies have also suggested that organophosphate-induced respiratory failure results from local effects of organophosphates acting on brainstem circuits underlying respiratory rhythmogenesis, and on lung tissues underlying pulmonary secretory, airway, and vascular function \[[@B29]\]. Finally, Chuang et al \[[@B30]\] confirmed that patients with QTc prolongation had a higher mortality rate and a higher incidence of respiratory failure than patients without QTc prolongation.

The retrospective nature, small patient population, short follow-up duration, and inadequate definition of new-onset diabetes mellitus limit the certainty of our conclusions. Therefore, a prospective study with larger patient numbers, longer follow up, and strict assessment of new-onset diabetes mellitus (such as glycated hemoglobin or oral glucose tolerance test) are required to confirm our conclusion.

Conclusions
===========

Diabetes mellitus status might not increase mortality risk following acute large-dose exposure to organophosphates, and the risk of new-onset diabetes mellitus also might be minimal in the short term. Larger prospective studies with formal testing for diabetes at later times post-exposure are required.
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